Skip to content
DataLookout
Menu

NCT07844512

Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing Bariatric Surgery

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change.

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 1, 2026 to Oct 28, 2026
    • Study sites: 0 to 1
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Quality of Recovery-15 (QoR-15) Score at 24 Hours After Surgery
Timeframe: 24 hours after bariatric surgery

Arms and interventions

Tegileridine GroupExperimental
Standard Opioid GroupActive comparator

Drugs: Tegileridine (tegileridine fumarate injection, IV), Sufentanil

Sites

1 site in 1 country

  • The First Hospital of Jilin UniversityChangchun, Jilin, China